In Brief: SmithKline Beecham Clinical Labs/Hyseq
This article was originally published in The Gray Sheet
Executive Summary
SmithKline Beecham Clinical Labs/Hyseq: Enter agreement whereby SBCL will license the "Format-1 A" process of Hyseq's sequencing-by-hybridization DNA diagnostic technology, which enables the detection of normal and mutated genes. The license is non-exclusive except for tests Hyseq develops specifically for SBCL. SBCL says it will use the Hyseq technology to develop new diagnostics, including tests for "previously unknown" genetic mutations...